申请人:Eli Lilly and Company
公开号:US08093302B2
公开(公告)日:2012-01-10
The present invention relates to novel tetralin ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.
本发明涉及新型四氢萘ER-β激动剂化合物、其药物组合物以及使用这些化合物治疗ER-β介导的疾病,如夜尿症、梗阻性尿路疾病、良性前列腺增生、肥胖症、痴呆症、高血压、失禁、结肠癌、前列腺癌、不孕症、抑郁症、白血病、炎性肠病和关节炎的用途。